Sunwin International Neutraceuticals, Inc. Announces Expansion of Production of Natural, Low Calorie Sweetener

Company Forecasts $8 Million to $9 Million in Sales of Natural Sweetener Worldwide Upon Completion of New Production Line

BOCA RATON, FL -- (MARKET WIRE) -- 09/16/2004 -- Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in distribution and manufacturing of Chinese herbs, veterinary medicines and natural sweetener in China, announced today it has recovered sales of natural sweetener (beet sugar) in the first six months of 2004. The Company has achieved $2 million in sales of natural sweetener and $200,000 in net income in the first six months of 2004. Historically the company recognizes a significant portion of beet sugar sales in the 3rd and 4th quarter; as a result the Company forecasts 180 tons to 200 tons in sales or $5 to $6 million in sales and $600,000 in net income in 2004.

The sales of natural sweetener (beet sugar) in 2003 were affected by SARS. Due in part to increased demand, the average price of beet sugar increased 24% from $24,184 per ton in 2003 to $29,927 per ton in 2004.

Stevioside (beet sugar), a natural sweetener, is extracted from the leaves of the Stevia rebaudiana plant, as a food additive which is used in various products such as beverages, pastries, dairy products, candies, confections, and medicinal products. Stevioside is approximately 200 to 300 times sweeter than general sucrose, but it has only 1/300th of the calories and it is often referred to as the third generation of natural low calorie sweeteners.

The Company also announced it will expand production line for natural sweetener (beet sugar) in 2004. The new production line should be able to produce 300 tons of natural sweetener per year and generates annual sales of $8 to $9 million upon completion.

Mr. Baozhong Yuan, CEO of Sunwin, commented, "Our goal is to gain acceptance in the multi billion dollar global sweetener market. We believe natural, low calorie sweetener (beet sugar) will eventually replace synthetic sweetener worldwide in the near future. Natural sweetener provides much better taste than synthetic sweetener while it does not have any side effects to human organs and systems as synthetic sweetener has. Our current production of natural sweetener accounts for about 16% of worldwide production and we expect to increase our market share worldwide to 30% upon the completion of this new production line in 2005."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. ("Sunwin") is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, nutraceutical products, natural sweetener (beet sugar), and animal medicine prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more information about Sunwin, please visit

Safe Harbor Statement

Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Sunwin International Neutraceuticals, Inc.
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.